Paediatric renal tumours: perspectives from the SIOP–RTSG

Article metrics


The >90% rates of overall survival for children with Wilms tumour are remarkable and have been achieved at the same time as reducing treatment for most patients. However, beneath this headline figure, 20% of patients still relapse after first-line therapy and up to 25% of survivors report severe late effects. The aim of the SIOP–RTSG is to improve outcomes and to reduce acute and late treatment toxic effects in all children.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Pritchard-Jones, K. et al. Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet 386, 1156–1164 (2015).

  2. 2

    de Kraker, J. et al. Wilm's tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. J. Clin. Oncol. 8, 1187–1190 (1990).

  3. 3

    Gatta, G. et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5 — a population-based study. Lancet Oncol. 15, 35–47 (2014).

  4. 4

    Chagtai, T. et al. Gain of 1q as a prognosticbiomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: a SIOP renal tumours biology consortium study. J. Clin. Oncol. 34, 3195–3203 (2016).

  5. 5

    Gratias, E. J. et al. Association of chromosome 1q gain with inferior survival in favorable-histology wilms tumor: a report from the Children's Oncology Group. J. Clin. Oncol. 34, 3189–3194 (2016).

  6. 6

    Spreafico, F. et al. Treatment of relapsed Wilms tumors: lessons learned. Expert Rev. Anticancer Ther. 9, 1807–1815 (2009).

  7. 7

    Graf, N. et al. Is the absolute blastema volume after preoperative chemotherapy in nephroblastoma relevant for prognosis? Pediatr. Blood Cancer 57, 741–742 (2011).

  8. 8

    Wegert, J. et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, 298–311 (2015).

  9. 9

    Walz, A. L. et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27, 286–297 (2015).

  10. 10

    Hales, P. W., Olsen, Ø. E., Sebire, N. J., Pritchard-Jones, K. & Clark, C. A. A multi-Gaussian model for apparent diffusion coefficient histogram analysis of Wilms' tumour subtype and response to chemotherapy. NMR Biomed. 28, 948–957 (2015).

Download references

Author information

Correspondence to Filippo Spreafico.

Ethics declarations

Competing interests

The author declare no competing financial interests.

Related links

Related links



Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading